Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185746 | 1.00 | CES2 (0.52) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL3196682 | 1.00 | CES2 (0.52) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL18953029 | 1.00 | CES2 (0.52) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL27822594 | 0.98 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL3185732 | 0.98 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL30576670 | 0.92 | CES2 (0.41) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL9388696 | 0.92 | CES2 (0.50) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL11784529 | 0.92 | CES2 (0.59) | CES2CES1 | |
| SCHEMBL11201948 | 0.90 | CES2 (0.57) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL9465217 | 0.88 | CES2 (0.59) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163049-B2 | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2015-10-20 | — | — | US | disclosed |
| EP-2266580-B1 | Medicament comprising an alkyl-rhamnose monomer for the treatment of inflammatory disorders | FABRE PIERRE DERMO COSMETIQUE (FR) | 2014-03-26 | — | — | EP | disclosed |
| EP-1682158-B1 | Cosmetic compositions comprising at least a rhamnose monomer for the cosmetic treatment of skins | FABRE PIERRE DERMO COSMETIQUE (FR) | 2011-05-25 | — | — | EP | disclosed |
| EP-2266580-A1 | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders | Pierre Fabre Dermo-Cosmétique (FR) | 2010-12-29 | — | — | EP | disclosed |
| US-20100069311-A1 | MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS | HOULMONT JEAN-PHILIPPE | 2010-03-18 | — | — | US | disclosed |
| US-7666847-B2 | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2010-02-23 | — | — | US | disclosed |
| US-20070134187-A1 | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders | CENTRE NATIONAL DE LA RECHESRCHE SCIENTIFIQUE (CNRS) (FR) | 2007-06-14 | — | — | US | disclosed |
| EP-1682158-A1 | MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Pierre Fabre Dermo-Cosmetique (FR) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005041983-A1 | MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069311-A1 | MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS | UGCG, UGGT1, TLR6 | CES2 665/4885MEN1 3713/4885FAAH 181/4885 |
| US-20070134187-A1 | Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders | UGCG, TLR6, CD68 | CES2 949/4885MEN1 3662/4885FAAH 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.